GE Acquires Cell Culture Media and Sera Assets from Thermo Fisher Scientific - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GE Acquires Cell Culture Media and Sera Assets from Thermo Fisher Scientific



GE Healthcare and Thermo Fisher Scientific have entered into an agreement for GE to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion. The acquisition will allow GE to expand its technologies for the discovery and manufacturing of new medicines, vaccines, and diagnostics in its life sciences business. GE’s acquisition of the businesses, which is subject to regulatory approvals, is anticipated to close in the first part of 2014.

Thermo Fisher’s HyClone cell culture media and sera products are complementary to GE Healthcare’s technologies for cell biology research and biopharmaceutical manufacturing, allowing GE to offer a wider range of technologies and services.

GE will also acquire Thermo Fisher’s gene modulation technologies, which complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line, which extends GE’s existing technologies in protein analysis and medical diagnostics.

The three acquired businesses generated combined annual revenues of approximately $250 million in 2013.

In November 2013, the European Commission (EC) cleared the proposed acquisition of Life Technologies by Thermo Fisher Scientific conditioned on Thermo Fisher Scientific’s divestments of three business lines, including media and sera for cell culture. The EC determined that in these areas, the merger, as initially notified, would have significantly reduced competition.

Source: GE Healthcare

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here